Mr. USA Pageant Records - Accession 107 - M46 (61)

The Mr. USA Pageant Records consists of letters, news releases, newspaper clippings, memorabilia, and photographs relating to the operation of the pageant and the publicity generated from the pageant. The Mr. USA Pageant was held on May 13, 1977 in Charleston, SC as a spoof of traditional beauty pageants and was sponsored by the National Organization of Women (NOW).

The Azores Current System and the Canary Current from CTD and ADCP data

Se han eliminado páginas en blanco

Die Haftung des vorläufigen Insolvenzverwalters bei der Begründung von Masseverbindlichkeiten (§§ 21, 61 InsO)

Die Arbeit befasst sich mit der Haftungsproblematik des vorläufigen Insolvenzverwalters, dem das Insolvenzgericht bereits im Eröffnungsverfahren die Verwaltungs- und Verfügungsbefugnis über das schuldnerische Vermögen übertragen hat. Nach § 55 Abs. 2 InsO haben Verbindlichkeiten, die der vorläufige Insolvenzverwalter begründet hat, im eröffneten Verfahren den Rang von Masseverbindlichkeiten. Gleiches gilt im Fall der Inanspruchnahme von Gegenleistungen aus bereits bestehenden Dauerschuldverhältnissen. Für die von ihm dergestalt begründeten Masseverbindlichkeiten haftet der vorläufige Insolvenzverwalter im Fall eines späteren Forderungsausfalls gegenüber den Gläubigern persönlich, sofern er nicht den Entlastungsbeweis führen kann, dass bei Eingehung der Verbindlichkeit der spätere Ausfall nicht absehbar war (§§ 21, 61 InsO). Schwerpunkt der vorliegenden Arbeit ist die Herausarbeitung der Haftungsvoraussetzungen des § 61 InsO, der an ein pflichtwidriges Verhalten des (vorläufigen) Insolvenzverwalters anknüpft. Der vorläufige Verwalter hat, um einer Haftung nach §§ 21, 61 InsO zu entgehen, vor Eingehung neuer Masseverbindlichkeiten die zukünftige Massedeckung zu prüfen. Hierbei müssen die zukünftigen Einnahmen und Ausgaben im Wege einer Finanzplanung erfasst und bewertet werden. Die Herausarbeitung dieser in Literatur und Praxis bislang stiefmütterlich behandelten Problematik ist Kernthema der Dissertation.

Intracranial neoplasia in 61 cats: localisation, tumour types and seizure patterns

The purpose of this study was to analyse retrospectively a feline population with intracranial neoplastic diseases, to document seizure patterns in these animals and to determine whether partial seizures were more frequently associated with structural brain lesions then generalised seizures. In addition, a comparison was made within the population with intracranial neoplasia between two groups of cats: one with and one without seizures. Special emphasis was given to the evaluation of tumour type, localisation and size of the lesion and its correlation with seizure prevalence. Sixty-one cats with histopathological diagnosis of intracranial tumour were identified. Fourteen cats (23%; group A) had a history of seizure(s). Forty-seven cats (77%; group B) had no history of seizure(s). Generalised tonic-clonic seizures were seen in eight cats (57%) and were the most common seizure pattern in our cats with intracranial neoplasia. Clusters of seizures were observed in six cats. Status epilepticus was observed in one patient. The mean age of the cats was 7.9 years within group A (median 8.5) and 9.3 years (median 10) within group B. The cats with lymphoma within both groups were significantly younger than cats with meningioma. In both groups meningioma and lymphoma were confirmed to be the most frequent tumour type, followed by glial cell tumours. The prevalence of the seizures in patients with glial cell tumours was 26.7%, 26.3% in patients with lymphomas and 15% in cases with meningiomas. In 33 cases (54.1%) the tumours were localised in the forebrain, 15 tumours (24.6%) were in the brainstem, four (6.6%) in the cerebellum and nine tumours (14.7%) had multifocal localisation. Parietal lobe and basal ganglia mostly affected group A. In group B tumours were most frequently located in the parietal and frontal lobes as well as in the diencephalon. A positive association was documented between the localisation of a tumour in the forebrain and seizure occurrence.

Molecular and serological diagnosis of Bartonella infection in 61 dogs from the United States

Molecular diagnosis of canine bartonellosis can be extremely challenging and often requires the use of an enrichment culture approach followed by PCR amplification of bacterial DNA. HYPOTHESES: (1) The use of enrichment culture with PCR will increase molecular detection of bacteremia and will expand the diversity of Bartonella species detected. (2) Serological testing for Bartonella henselae and Bartonella vinsonii subsp. berkhoffii does not correlate with documentation of bacteremia. ANIMALS: Between 2003 and 2009, 924 samples from 663 dogs were submitted to the North Carolina State University, College of Veterinary Medicine, Vector Borne Diseases Diagnostic Laboratory for diagnostic testing with the Bartonella α-Proteobacteria growth medium (BAPGM) platform. Test results and medical records of those dogs were retrospectively reviewed. METHODS: PCR amplification of Bartonella sp. DNA after extraction from patient samples was compared with PCR after BAPGM enrichment culture. Indirect immunofluorescent antibody assays, used to detect B. henselae and B. vinsonii subsp. berkhoffii antibodies, were compared with PCR. RESULTS: Sixty-one of 663 dogs were culture positive or had Bartonella DNA detected by PCR, including B. henselae (30/61), B. vinsonii subsp. berkhoffii (17/61), Bartonella koehlerae (7/61), Bartonella volans-like (2/61), and Bartonella bovis (2/61). Coinfection with more than 1 Bartonella sp. was documented in 9/61 dogs. BAPGM culture was required for PCR detection in 32/61 cases. Only 7/19 and 4/10 infected dogs tested by IFA were B. henselae and B. vinsonii subsp. berkhoffii seroreactive, respectively. CONCLUSIONS AND CLINICAL IMPORTANCE: Dogs were most often infected with B. henselae or B. vinsonii subsp. berkhoffii based on PCR and enrichment culture, coinfection was documented, and various Bartonella species were identified. Most infected dogs did not have detectable Bartonella antibodies.